Abstract Introduction of Chimeric Antigen Receptors to NK cells has so far been the main
practical method for targeting NK cells to specific surface antigens. In contrast, T cell …

Purpose: Generation of antigen-specific T cells from patients with cancer employs large
numbers of peripheral blood cells and/or tumor-infiltrating cells to generate antigen …

Poor response of human malignant melanoma to currently available treatments requires a
development of innovative therapeutic strategies. Their evaluation should be based on …

Background: Tumor-infiltrating lymphocytes (TILs) and chimeric antigen receptor (CAR) T-
cell therapies have demonstrated promising, though limited, efficacy against melanoma …

Background Current FDA-approved therapeutic options for patients with metastatic
melanoma include dacarbazine, interleukin 2, ipilimumab, vemurafenib, dabrafenib, and …

It has been established in murine models that lymph nodes draining a progressively growing
tumor contain antigen-specific T cells capable of mediating protective immune responses …

Tumor antigens that might serve as potential targets for adoptive T-cell therapy have been
defined in different tumor entities, especially in malignant melanoma. To generate conditions …

PURPOSE In this study, we tested the effectiveness of a melanoma-associated antigen–
derived peptide, MART-1 27–35, in eliciting cellular immune responses in vivo in the context …

Chimeric antigen receptor (CAR) T cell therapy has proven clinically beneficial against B cell
acute lymphoblastic leukemia and non-Hodgkin's lymphoma. However, suboptimal clinical …

The genetic modification of CD8+ T cells using anti-tumor T-cell receptors (TCR) or chimeric
antigen receptors is a promising approach for the adoptive cell therapy of patients with …